Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

When to Consider Allogeneic Transplantation in CML.

Clinical lymphoma, myeloma & leukemia - 1 Aug 2016

Radich Jerald

Abstract excerpt

Tyrosine kinase inhibitor (TKI) therapy has radically altered the treatment strategy for chronic myeloid leukemia. Allogeneic transplantation, which over a decade ago was considered the definitive therapy for CML, is now appropriately used in cases where all TKIs are not tolerated, in cases of resistance to TKI therapy, or when the disease progresses from chronic phase to accelerated or blast phase.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Decision-Making
Share to Drug Resistance, Neoplasm
Share to Blast Crisis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fusion Proteins, bcr-abl

Share to Hematopoietic Stem Cell Transplantation

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Neoplasm Staging

Share to Transplantation, Homologous

Source

Identifiers

PMID: 27521333
DOI: 10.1016/j.clml.2016.02.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

When to Consider Allogeneic Transplantation in CML.PMID 27521333Read ↗

The impact of pretransplant use of tyrosine kinase inhibitors on allogeneic stem cell transplantation in patients with chronic myeloid leukemia - A single-institution retrospective studySemantic proximity Read ↗

Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era.Semantic proximity Read ↗

To transplant or not to transplant for adult acute myeloid leukemia: an ever-evolving decision.Semantic proximity Read ↗

Controversies and dilemmas in allogeneic transplantation for myelofibrosis.Semantic proximity Read ↗

Three decades of transplantation for chronic myeloid leukemia: what have we learned?Semantic proximity Read ↗

A limited but necessary indication of stem cell transplantation for chronic myelogeneous leukemia in the era of tyrosine kinase inhibitors.Semantic proximity Read ↗

[Key points in second-line therapy for chronic myeloid leukemia].Semantic proximity Read ↗

T315I-mutated chronic myeloid leukemia with blast crisis relapse 10 years after allo-HSCT: A case report of second transplantation combined with olverembatinib maintenance therapy.Semantic proximity Read ↗

Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation–related imatinib failureSemantic proximity Read ↗

Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic TransplantationSemantic proximity Read ↗

Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations.Semantic proximity Read ↗

Development of TCR-T cell therapy targeting mismatched HLA-DPB1 for relapsed leukemia after allogeneic transplantationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.